Quantum Computing in Radiopharmacy: Modeling, Optimization, and Clinical Translation
Quantum Frontiers in Radiopharmacy
Volume 1, Issue 3
Blessed Yahweh
The MindBook Group, Akwa Ibom State, Nigeria.
Abstract
Radiopharmacy sits at the intersection of nuclear physics, chemistry, medicine, and data science. Its core challenges include accurate radionuclide modeling, efficient radiotracer design, dose optimization, and robust quality control under strict regulatory constraints. Quantum computing, particularly in hybrid quantum–classical form, is emerging as a viable scientific tool for addressing these challenges. This issue examines how quantum computation and quantum-inspired methods are reshaping radiopharmaceutical research, with emphasis on molecular simulation, nuclear interaction modeling, production optimization, and data-driven clinical translation.
1. Introduction
Radiopharmaceutical development relies on precise understanding of molecular binding, nuclear decay pathways, and radiation–matter interactions. Classical computational approaches, while mature, often depend on approximations that limit predictive accuracy, especially for complex radionuclide–ligand systems and multiscale transport phenomena [1], [4]. Recent advances in quantum computing suggest alternative pathways for modeling these systems more faithfully, not by replacing existing tools, but by extending their physical reach [6], [7].
2. Molecular Modeling and Radiotracer Design
At the molecular level, radiopharmacy faces challenges similar to conventional drug discovery, compounded by radioactive decay and coordination chemistry constraints. Quantum algorithms for electronic structure estimation offer improved treatment of electron correlation effects relevant to radionuclide chelation, ligand stability, and target affinity [2], [5].
Hybrid quantum–classical pipelines are increasingly proposed for radiotracer design, where quantum subroutines refine molecular energy landscapes while classical optimizers handle large-scale screening [9], [11], [14]. These approaches are particularly relevant for beta- and gamma-emitting tracers, where small changes in molecular structure can significantly alter biodistribution and clearance profiles.
3. Nuclear Interactions and Dose Modeling
Radiopharmacy is inseparable from radiation physics. Accurate dose estimation requires modeling particle transport, energy deposition, and interaction cross sections within heterogeneous biological media. Quantum-inspired methods are being explored to improve these models by embedding physically informed representations into learning frameworks that outperform purely empirical approaches in low-data regimes [1], [10].
While quantum hardware is not yet used for direct Monte Carlo replacement, quantum-enhanced modeling shows promise in refining kernel approximations, uncertainty quantification, and parameter inversion for patient-specific dosimetry [6], [7].
4. Production, Quality Control, and Optimization
Radionuclide production and radiopharmaceutical preparation involve tightly coupled processes, including irradiation, separation, synthesis, and quality assurance. These workflows generate complex, nonlinear datasets constrained by time, decay kinetics, and regulatory thresholds.
Quantum machine learning models have been proposed for optimizing production yield, predicting impurity profiles, and supporting adaptive quality control under uncertainty [3], [12]. Hybrid optimization schemes allow quantum routines to explore constrained solution spaces more efficiently, while classical systems enforce operational feasibility [11].
5. Clinical Translation and Decision Support
From a translational perspective, radiopharmacy increasingly depends on data-driven decision support, spanning tracer selection, activity prescription, and risk assessment. Quantum-enhanced learning models are being investigated for patient stratification and treatment response prediction, particularly where datasets are small or noisy, as is common in early-stage radiopharmaceutical trials [8], [12], [13].
These developments align with a broader shift toward precision nuclear medicine, where computational fidelity directly influences safety, efficacy, and regulatory confidence.
6. Limitations and Near-Term Outlook
Despite growing interest, quantum computing in radiopharmacy remains constrained by hardware noise, limited qubit counts, and algorithmic maturity. Current impact is therefore concentrated in hybrid and quantum-inspired approaches rather than full quantum advantage.
Over the next decade, progress is expected to focus on:
Error-mitigated quantum simulations for radionuclide chemistry
Integration of quantum models with AI-driven radiopharmacy pipelines
Physically interpretable quantum learning frameworks for clinical use
Incremental gains in accuracy and robustness, rather than disruptive replacement, are the realistic trajectory.
7. Conclusion
Quantum computing introduces a new scientific layer to radiopharmacy, grounded in physics rather than speculation. Its value lies in deeper molecular insight, improved nuclear modeling, and more reliable decision support under uncertainty. As hybrid quantum–classical methods mature, radiopharmacy stands to benefit not from faster computation alone, but from models that better reflect the true complexity of radioactive systems.
References
[1] H. Liu, “Implementations of quantum computing in medicine: Evidence from drug discovery, genomics, and medical imaging,” Highlights in Science, Engineering and Technology, 2025, doi: 10.54097/sa5x8f65.
[2] M. S. Jeyalakshmi, A. A. Sayyad, A. Deepak, et al., “Quantum computing and healthcare: Drug discovery and molecular simulation with machine learning,” Int. J. Intell. Syst. Appl. Eng., vol. 12, no. 14s, 2024.
[3] S. Sharma and D. Kumari, “Quantum computing for healthcare applications,” Int. J. Development Research, 2024.
[4] M. W. Arshad, I. Murtza, and M. A. Arshad, “Applications of quantum computing in health sector,” J. Data Science and Intelligent Systems, vol. 1, no. 1, pp. 19–24, 2023, doi: 10.47852/bonviewJDSIS3202656.
[5] P. Sharma, “Quantum computing in drug design: Enhancing precision and efficiency in pharmaceutical development,” Sage Science Review of Applied Machine Learning, vol. 7, no. 1, pp. 1–9, 2024.
[6] Quantum Computing in Medicine, MDPI, 2025.
[7] “Quantum computing revolution in healthcare: A systematic review of applications, issues and future directions,” Artificial Intelligence Review, vol. 58, Art. no. 389, 2025.
[8] “Quantum computing in medical imaging,” Int. J. Futuristic Innovation in Engineering, Science and Technology, 2025.
[9] “A hybrid quantum computing pipeline for real-world drug discovery,” PubMed, 2024.
[10] H. Ali, “Quantum computing and AI in healthcare: Accelerating complex biological simulations, genomic data processing, and drug discovery innovations,” World J. Advanced Research and Reviews, vol. 20, no. 2, pp. 1466–1484, 2023, doi: 10.30574/wjarr.2023.20.2.2325.
[11] A. Smith and E. Guven, “Bridging quantum and classical computing in drug design: Architecture principles for improved molecule generation,” arXiv, 2025.
[12] M. Bertl, A. Mott, S. Sinno, and B. Bhalgamiya, “Quantum machine learning in precision medicine and drug discovery,” arXiv, 2025.
[13] S. Maniscalco et al., “Quantum network medicine: Rethinking medicine with network science and quantum algorithms,” arXiv, 2022.
[14] “Quantum-machine-assisted drug discovery: Survey and perspective,” Preprints.org, 2024.